Study:
A Phase III Trial Comparing ARA-C/High-Dose Mitoxantrone ("ALL-2`) to A Standard Vincristine/Prednisone Based Regimen (`L-20`) as Induction Therapy For Adult Patients With Acute Lymphoblastic Leukemia (ALL): The ALL-4 Protocol
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining more than one drug may kill more tumor cells. It is
not yet known which regimen of combination chemotherapy is more effective for acute
lymphoblastic leukemia, lymphoblastic lymphoma, or chronic myelogenous leukemia.
Purpose:
This randomized phase III trial is studying two different chemotherapy regimens and
comparing them to see how well they work in treating adults with acute lymphoblastic
leukemia, lymphoblastic lymphoma, or chronic myelogenous leukemia.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Leukemia
Lymphoma |
Biological: dactinomycin
Biological: sargramostim
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: mercaptopurine
Drug: methotrexate
Drug: mitoxantrone hydrochloride
Drug: pegaspargase
Drug: prednisone
Drug: vincristine sulfate
Radiation: radiation therapy |
Phase 3 |
Verified by
Memorial Sloan-Kettering Cancer Center
April, 2013
Sponsored by: Memorial Sloan-Kettering Cancer Center
Information provided by: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov identifier: NCT00002766
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Nicole Lamanna, MD., Study Chair